CA
SRPT icon

Clearstead Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Clearstead Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$144K Hold
8,000
– – ﹤0.01% 1165
2026
Q1 		$174K Buy
8,000
+1,815
+29% +$35.1K ﹤0.01% 1013
2025
Q4 		$133K Sell
6,185
-6,184
-50% -$130K ﹤0.01% 1039
2025
Q3 		$238K Buy
12,369
+2,669
+28% +$47.6K ﹤0.01% 839
2025
Q2 		$166K Sell
9,700
-1,087
-10% -$46.4K ﹤0.01% 928
2025
Q1 		$688K Sell
10,787
-992
-8% -$104K 0.01% 495
2024
Q4 		$1.43M Hold
11,779
– – 0.02% 348
2024
Q3 		$1.47M Buy
11,779
+3,147
+36% +$435K 0.02% 348
2024
Q2 		$1.36M Buy
8,632
+7,697
+823% +$989K 0.02% 337
2024
Q1 		$123K Hold
935
– – 0.01% 561
2023
Q4 		$90.2K Sell
935
-447
-32% -$42.9K ﹤0.01% 609
2023
Q3 		$168K Buy
1,382
+66
+5% +$7.46K 0.01% 452
2023
Q2 		$151K Buy
1,316
+961
+271% +$124K 0.01% 482
2023
Q1 		$48.9K Buy
+355
New +$46K ﹤0.01% 668
2022
Q4 		– Sell
-8
Closed -$1K – 1372
2022
Q3 		$1K Hold
8
– – ﹤0.01% 1196
2022
Q2 		$1K Hold
8
– – ﹤0.01% 1223
2022
Q1 		$1K Hold
8
– – ﹤0.01% 1323
2021
Q4 		$1K Sell
8
-252
-97% -$21.5K ﹤0.01% 1215
2021
Q3 		$24K Buy
260
+252
+3,150% +$19.4K ﹤0.01% 758
2021
Q2 		$1K Hold
8
– – ﹤0.01% 1196
2021
Q1 		$1K Buy
+8
New +$738 ﹤0.01% 1069

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Clearstead Advisors's SRPT Position: Q2 2026 in Review

Clearstead Advisors held its Sarepta Therapeutics (SRPT) position steady in Q2 2026 at 8,000 shares worth $144K. The position accounts for ﹤0.01% of the portfolio, ranked #1165.

Clearstead Advisors first reported a position in SRPT in Q1 2021 and has held it in 21 quarters since. The position peaked at $1.47M in Q3 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Clearstead Advisors held 8,000 shares of Sarepta Therapeutics worth $144K as of Q2 2026.
  • Clearstead Advisors left its Sarepta Therapeutics share count unchanged in Q2 2026.
  • Sarepta Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1165 holding.
  • Clearstead Advisors first reported a position in Sarepta Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • Clearstead Advisors's Sarepta Therapeutics position peaked at $1.47M in Q3 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.